The study, led by King's College London, found that of more than 1.2 million adults who received at least one dose of either the Pfizer-BioNTech, Oxford-AstraZeneca, or Moderna vaccine, between December 2020 and July 2021, fewer than 0.5 per cent reported a breakthrough infection more than 14 days after their first dose.
An "individualised assessment is necessary to determine whether a person's long Covid condition or any of its symptoms substantially limits a major life activity", according to the HHS guidance
The new studies of the condition that will investigate everything from brain fog to ongoing breathlessness, using a new technique to detect hidden lung damage.
